Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients
Journal of Comparative Effectiveness Research · 2024
DOI: 10.57264/cer-2024-0058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Filip Stanicic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics & Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON L5A 2X7, Canada. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, Health Care Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Exploring the healthcare costs and resource use among privately insured US patients with post-traumatic stress disorder (PTSD).
Methods
This study used Merative MarketScan data. The index date was defined as the first PTSD claim. Study period included a 1-year pre-index and 2-year post-index follow-up. Cases with only acute PTSD, cancer, or insurance gap during the study period were excluded. The PTSD with (PwC) and PTSD without comorbidities (PwoC) cohorts were defined by the presence/absence of comorbid mental health conditions (schizophrenia, bipolar and major depressive disorder). Baseline PTSD (BP) cohort included PwoC cases with only index PTSD event and without FDA-approved PTSD medications or psychotherapy. Sub-analysis is conducted among patients with PTSD and substance/alcohol use disorder. Study cohorts were matched in a 1:1:1 ratio.
Results
The matched sample included 5076 patients (1681 PwC, 1681 PwoC, 1714 BP). PwC patients had higher 2-year PTSD-related costs than PwoC and BP patients ($3762 vs $1750 and $841; all p < 0.001). The same trend was noted among all-cause and anxiety-related costs. PwC patients had higher 2-year PTSD-related inpatient and emergency department (ED) rates than PwoC (10.2% vs 1.7% and 6.8% vs 2.6%, all p < 0.001) and inpatient and outpatient rates than BP (10.2% vs 2.1% and 98.0% vs 93.1%; all p ≤ 0.004). The sub-analysis had 3776 patients (3154 PwC, 537 PwoC, 85 BP). PwC had higher 2-year PTSD-related costs than PwoC and BP ($7668 vs $2919 and $1,483; all p < 0.001). The same trend was noted in all-cause and anxiety-related costs. PwC also had higher 2-year PTSD-related inpatient and ED rates than PwoC (25.6% vs 10.4% and 12.7% vs 5.2%; all p < 0.001) and inpatient and outpatient rates than BP (25.6% vs 8.2% and 95.5% vs 84.7%; all p < 0.001).
Conclusion
PTSD is associated with high healthcare costs and resource use. The highest economic burden was observed in patients with PTSD and mental health comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Economics & Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON L5A 2X7, Canada.
- Lykos Therapeutics, 3141 Stevens Creek Blvd #40547, San Jose, CA 95117, USA.
ORCID-Profile: Filip Stanicic, Vladimir Zah, Dimitrije Grbic
Zitieren
APA
Stanicic, F., Zah, V., Grbic, D., Angelo, D., & Bibeau, W. (2024). Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0058
Vancouver
Stanicic F, Zah V, Grbic D, Angelo D, Bibeau W. Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0058
BibTeX
@article{Stanicic2024,
author = {Stanicic, Filip and Zah, Vladimir and Grbic, Dimitrije and Angelo, Debra de and Bibeau, Wendy},
title = {Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients},
journal = {Journal of Comparative Effectiveness Research},
year = {2024},
doi = {10.57264/cer-2024-0058}
}
EUVIMED